Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.54 |
| ▸ | ACACA | Q13085 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170291 | 0.91 | ACACB (0.53) | ACACBACACAALDH1A1NPC1RAB9A | |
| SCHEMBL10170259 | 0.91 | ACACB (0.52) | ACACBACACALMNAMAPT | |
| SCHEMBL551283 | 0.91 | ACACB (0.52) | ACACBACACAALDH1A1NPC1RAB9A | |
| SCHEMBL552034 | 0.90 | ACACB (0.51) | ACACBACACALMNAMAPT | |
| SCHEMBL551407 | 0.90 | ACACB (0.53) | ACACBACACANPC1RAB9ALMNA | |
| SCHEMBL10170420 | 0.89 | ACACB (0.51) | ACACBACACA | |
| SCHEMBL10169985 | 0.89 | ALDH1A1 (0.43) | ACACBACACAALDH1A1NPC1RAB9A | |
| SCHEMBL10170368 | 0.88 | ACACB (0.52) | ACACBACACALMNAMAPT | |
| SCHEMBL551034 | 0.88 | ACACB (0.50) | ACACBACACALMNAMAPT | |
| SCHEMBL10170534 | 0.88 | ACACB (0.50) | ACACBACACANPC1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | ACACA, ACAT1, ACACB | ACACB 3/4885ACACA 1/4885ALDH1A1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.